Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Persistent Epithelial Defect Management Market Snapshot (2023 to 2033)

The global persistent epithelial defect management market is slated to reach a valuation of US$ 8.5 billion in 2023. According to Future Market Insights, the market is expected to grow at an 18% CAGR until 2033, being valued at US$ 44.49 billion.

The persistent epithelial defect (PED) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted PED symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Persistent Epithelial Defect (PED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Persistent epithelial defects (PEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. In recent years, PED awareness has increased with increased research activities from various spectrums of ophthalmology research. However, the actual frequency of PED is not known as of now, but some studies have estimated the frequency based on the causative occurrence of the disease with underlying conditions.

Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect, and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others.

The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Disruptions in this protective layer can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and decreased visual acuity.

It covers the details of conventional and current medical therapies and diagnoses available in the persistent epithelial defect (PED) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The Persistent Epithelial Defect (PED) market report gives a thorough understanding of PED symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PED symptoms of treatment algorithms and treatment guidelines for PED symptoms in the US, Europe, and Japan.

Attributes Details
Expected Market Value (2023) US$ 8.5 billion
Projected Forecast Value (2033) US$ 44.49 billion
Global Growth Rate (2023 to 2033) 18%
Forecast period 2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 To 2022 Persistent Epithelial Defect Management Market Demand Analysis Vs. Forecast 2023 to 2033

The global persistent epithelial defect management market is expected to surge at a CAGR of 18% for the forecast period compared to the historic CAGR from 2018 to 2022 of 19.3%, as per Future Market Insights, a provider of market research and com compared to the competitive intelligence.

Patients usually present with pain, watering, and foreign body sensation in the affected eye. However, these features may be absent in neurotrophic PEDs. There may be blurring of vision, redness, photophobia, pain with blinking, and eye movements. PED, if left untreated, can lead to corneal inflammation, infection, ulceration, scarring, melting, and even perforation due to disruption of the protective epithelial and stromal layers of the cornea.

A comprehensive history comprising duration, mechanism of trauma, prior treatment received and surgeries, associated ocular and systemic comorbidities, family history, and immune status will help arrive at an etiological diagnosis and allow more specific treatment. Distinguishing an epithelial defect from a PED can be done based on the time required for complete healing after an injury. An epithelial defect recovers by 7 to 10 days, while a PED will not heal even after two weeks, and such a patient is usually refractory to standard treatments and supportive care

But nowadays, a thorough examination of both the eyes, adnexa, and systemic assessment is of utmost importance to determine the etiology. Fluorescein staining is used to photograph the defect for serial monitoring and measuring the size, depth, and location of the epithelial defect using a slit lamp. Deeper PEDs take longer to absorb the fluorescein into the stroma and frequently have grayish-white edges with heaped-up epithelium. Associated signs of infection, such as underlying haze and infiltrates and anterior chamber inflammation, must be actively sought. There can be associated basement membrane dystrophies, nodular degeneration, dendrites, limbal stem cell deficiency, conjunctival injection, features of superior limbic keratoconjunctivitis, allergic conjunctivitis, foreign body, and concretions. It is essential to assess dry eyes using the Schirmer test and tear-film breakup time. The Rose Bengal dye stains devitalized epithelial cells, implying impaired tear function, regardless of gross tear flow.

The diagnosis of PED is primarily clinical. It can be supplemented by investigations that help to quantify the lesion and track its progress. AS-OCT is a non-invasive definitive technique for quantifying epithelial thickness and loss over time, especially in areas of corneal thinning and scarring. Confocal microscopy is a technique that allows the imaging of thin layers of living corneal cellular structures in real time. In vivo HRT-II confocal microscopy has been designed for studying the superficial and peripheral corneal and conjunctival epithelium.

For systemic comorbidities, relevant systemic investigations must be conducted. For example, in patients with diabetes, fasting and postprandial blood sugar levels and HbA1C values are measured. Vitamin A deficiency can be confirmed by measuring serum retinol-binding protein and zinc levels. Rheumatoid factor, anti-cyclic citrullinated peptide (anti-CCP) antibody for rheumatoid arthritis, antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) antibody for systemic lupus erythematosus (SLE), anti-Ro/SSA, and anti-La/SSB antibody for Sjogren syndrome are all autoimmune indicators.

Prominent Growth Drivers Influencing Persistent Epithelial Defect Management Market

Increased Partnerships and Collaborations

The increasing partnerships and collaborations between numerous companies boost market growth. For instance, in October 2017, Bio-Tissue entered a strategic agreement with Optima Pharmazeutische GmbH, a pharmaceutical company that offers otorhinolaryngology, ophthalmology, and pneumology products. This agreement helps the company to distribute its Natural Ocular Cleanser in Germany. Thus, all these collaborations boost the growth of the market.

Higher Demand for Hospitals

The increasing demand for hospitals surges the market grows rapidly. Most chronic disease diagnostics are majorly performed in hospitals since they are very complex and it requires technologically advanced products and thus this is boosting the market for hospital/clinical laboratories.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Persistent Epithelial Defect Management Market Demand?

Lack of skilled professionals

The lack of qualified healthcare professionals who cannot treat the patients with appropriate treatments could reduce the growth of the persistent corneal epithelial defect treatment market over a forecast period.

High Cost of Treatment

The enormous expenditure that is required for setting up these techniques hinders market growth. Numerous market players make huge investments in installing new and advanced machines to faster the process and in return, the cost is increased.

This persistent corneal epithelial defects treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

Region-wise Analysis

What Is the Outlook of the North American Persistent Epithelial Defect Management Market?

The presence of key players and increasing initiatives are accelerating the growth

North America’s persistent epithelial defects treatment market is expected to witness significant growth during the forecast period. Although numerous therapies exist and a growing number of novel approaches are evolving, treatment of this disease can still be quite challenging.

It is necessary to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. The introduction of the latest technology development which offers various therapies for treating various complications caused by the disorder and the rise in the incidence of dry eye syndrome boosts the market growth.

The market in North America was valued at US$ 98.8 million in 2021. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Future Market Insights team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

What Can Be Expected from The European Persistent Epithelial Defect Management Market for Treatment?

The persistent epithelial defects treatment market is projected to witness significant growth during the forecast period. Although several therapies exist and an increasing number of novel approaches are evolving, treatment of this disease can still be quite challenging. It is essential to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing.

The introduction of the latest technology development offers numerous therapies for treating several complications caused by the disorder and the increase in the incidence of market growth. The expected CAGR of the persistent epithelial defects treatment market in Europe is likely to amount to 17.8% from 2023 to 2033.

What Can Be Expected from The Asia Pacific Persistent Epithelial Defect Management Market for Treatment?

The Asia-Pacific persistent epithelial defects treatment market is projected to witness significant growth during the forecast period. Although several therapies exist and an increasing number of novel approaches are evolving, treatment of this disease can still be quite challenging. It is essential to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing.

The introduction of the latest technology development offers numerous therapies for treating several complications caused by the disorder and the increase in the incidence of market growth. A growth rate in the persistent epithelial defects treatment market in the forecast period 2023-2033. The expected CAGR in the Asia Pacific is expected to be around 17.7% in the mentioned forecast period.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Type of Persistent Epithelial Defect Management Market Treatment is Most Prevalent?

The epithelial/limber segment will gain the dominant market share

Over the course of the forecast period, the epithelial/limber segment of disease type is anticipated to occupy a significant share of the global persistent epithelial defect management treatment market. In 2023, this category is also anticipated to acquire revenue share.

Due to their superior therapeutic activity, the epithelial/limber segment subgroup of disease types occupies a leading position in the worldwide persistent epithelial defect market. This is so because, epithelial cell migration and corneal epithelial stem cells in the limbus are crucial to regenerate the tissue after an insult to the corneal epithelium. Therefore, limbal stem cell deficiency (LSCD) often results in the inability of epithelial regeneration, stromal melting, scarring, persistent epithelial defects, corneal conjunctivalization, and neovascularization.

One of the common causes of severe limbal stem cell deficiency is an alkali-induced chemical injury from lye, household cleaning solutions, and fertilizers. Such factors are expected to accelerate the growth prospects for persistent epithelial defect management treatment from 2023 to 2033. The way to cure epithelial/limber disease is when the limbal stem cell deficiency has not yet fully developed, it can be treated with eye drops. However, in severe cases, limbal stem cell transplantation is regarded as the best option.

Which Distribution Channel is expected to gain traction from 2023 to 2033?

The demand for hospital/clinical laboratories will be more during the forecast period.

According to a report by Future Market Insights, the hospital/clinical laboratories would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.

Due to the growing number of people visiting hospitals for advice on treatment related to epithelial/limber disease, the hospital/clinical laboratory sector is anticipated to dominate the worldwide persistent epithelial defect management market.

As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.

How Competitive is the Market for Persistent Epithelial Defect Management Treatment?

The persistent epithelial defects management treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the persistent corneal epithelial defects treatment market.

Some of the important developments of the key players in the market are

  • Kala Pharmaceuticals acquired Combangio, expanding its pipeline with a clinical-stage novel biologic for the treatment of Persistent Epithelial Defect (PED) and other rare ocular surface diseases.
  • Nexagon has a market advantage in the US, as it received orphan drug designation from the FDA. It is being developed by OcuNexus Therapeutics in partnership with Eyevance Pharmaceuticals. Currently, the drug is under phase II studies for PED.

Key players operating in the persistent epithelial defects treatment market t include

  • Dompe Farmaceutici
  • OcuNexus Therapeutics
  • Eyevance Pharmaceuticals
  • Noveome Biotherapeutics
  • RegeneRx Biopharmaceuticals
  • Recordati Rare Diseases
  • Mimetech
  • Johnson & Johnson Services Inc.
  • Bausch Health Companies Inc.
  • Integra Lifesciences

Report Scope

Report Attribute Details
Growth Rate 18% CAGR
Base Year Estimation 2022
Market Value in 2023 US$ 8.5 billion
Market Value in 2033 US$ 44.49 billion
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units US$ billion for Value and CAGR from 2023 to 2033
Reports Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Disease Type
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • United Kingdom
  • Spain
  • Germany
  • Italy
  • France
  • China
  • Japan
  • South Korea
  • India
  • Malaysia
  • Singapore
  • Thailand
  • South Africa
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Dompe Farmaceutici
  • OcuNexus Therapeutics
  • Eyevance Pharmaceuticals
  • Noveome Biotherapeutics
  • RegeneRx Biopharmaceuticals
  • Recordati Rare Diseases
  • Mimetech
  • Johnson & Johnson Services Inc.
  • Bausch Health Companies Inc.
  • Integra Lifesciences
Customization Scope Available on Request

Key Segments Profiled in the Persistent Epithelial Defect Management Market Report

Disease Type:

  • Epithelial/Limbal
  • Inflammatory Disease
  • Neurotrophic Disease
  • Others

End User:

  • Hospitals/Clinical Laboratories
  • Physician Offices
  • Reference Laboratories
  • Other End Users

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Current Persistent Epithelial Defect Management Market Valuation?

The market is estimated to secure a valuation of US$ 8.5 billion in 2023.

Which Countries Dominate the Global Market?

The United States, Japan, and China dominate the global market.

Which Country is Set to Register Exponential Growth in Persistent Epithelial Defect Management Market?

The United States may witness significant growth in the market.

What is the Growth Forecast for Persistent Epithelial Defect Management Market?

The market is forecast to register a CAGR of 18% through 2033.

What is the Projected Size of the Market by 2033?

The global market size will reach US$ 44.49 billion by 2033.

Table of Content

1. Executive Summary | Persistent Epithelial Defect Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033

        5.3.1. Epithelial/limbal

        5.3.2. Inflammatory disease

        5.3.3. Neurotrophic disease

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospital/Clinical Laboratories

        6.3.2. Physician Offices

        6.3.3. Reference Laboratories

        6.3.4. Other End Users

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia

        7.3.5. East Asia

        7.3.6. Oceania

        7.3.7. Middle East & Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States

            8.2.1.2. Canada

        8.2.2. By Disease Type

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Disease Type

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Disease Type

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Type

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Disease Type

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Type

        10.3.3. By End User

    10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Rest of South Asia

        11.2.2. By Disease Type

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Type

        11.3.3. By End User

    11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Disease Type

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Type

        12.3.3. By End User

    12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Australia

            13.2.1.2. New Zealand

        13.2.2. By Disease Type

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Type

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of Middle East & Africa

        14.2.2. By Disease Type

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Type

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Disease Type

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Disease Type

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Disease Type

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Disease Type

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Disease Type

            15.5.2.2. By End User

    15.6. United kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Disease Type

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Disease Type

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Disease Type

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Disease Type

            15.9.2.2. By End User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Disease Type

            15.10.2.2. By End User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Disease Type

            15.11.2.2. By End User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Disease Type

            15.12.2.2. By End User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Disease Type

            15.13.2.2. By End User

    15.14. China

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Disease Type

            15.14.2.2. By End User

    15.15. Japan

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Disease Type

            15.15.2.2. By End User

    15.16. South Korea

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Disease Type

            15.16.2.2. By End User

    15.17. Australia

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Disease Type

            15.17.2.2. By End User

    15.18. New Zealand

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Disease Type

            15.18.2.2. By End User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Disease Type

            15.19.2.2. By End User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Disease Type

            15.20.2.2. By End User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Disease Type

            15.21.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Disease Type

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Dompe Farmaceutici

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. OcuNexus Therapeutics

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Eyevance Pharmaceuticals

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Noveome Biotherapeutics

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. RegeneRx Biopharmaceuticals

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Recordati Rare Diseases

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Mimetech

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Johnson & Johnson Services, Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Bausch Health Companies Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Integra Lifesciences

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Fuchs Endothelial Corneal Dystrophy (FECD) Market

Published : December 2022

Healthcare

Corneal Ulcer Treatment Market

Published : June 2022

Explore Healthcare Insights

View Reports

Persistent Epithelial Defect Management Market